Vertex Pharmaceuticals announced a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access CASGEVY (exagamglogene autotemcel). CASGEVY is the first and only gene editing therapy approved for these conditions in Europe.
Italy has the largest TDT population in Europe, with approximately 5,000 people aged 12 and older living with TDT and around 2,300 with SCD. This agreement is significant for expanding access to this one-time transformative treatment in a key European market.
Italy joins other countries that have signed reimbursement agreements for CASGEVY, including Austria, Bahrain, Denmark, England, the Kingdom of Saudi Arabia, and the United Arab Emirates. This further broadens the global patient reach for CASGEVY.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.